[1]
|
S. L. Zweizig, “Cancer of the Kidney,” Clinical Obstetrics and Gynecology, Vol. 45, No. 3, 2002, pp. 884-891.
http://dx.doi.org/10.1097/00003081-200209000-00035
|
[2]
|
S. Pyrhonen, E. Salminen, M. Ruutu, T. Lehtonen, M. Nurmi, T. Tammela, et al., “Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine versus Vinblastine Alone in Patients with Advanced Renal Cell Cancer,” Journal of Clinical Oncology, Vol. 17, No. 9, 1999, pp. 2859-2867.
|
[3]
|
R. J. Motzer, B. A. Murphy, J. Bacik, L. H. Schwartz, D. M. Nanus, T. Mariani, et al., “Phase III Trial of Interferon Alfa-2a with or without 13-Cis-Retinoic Acid for Patients with Advanced Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 18, No. 16, 2000, pp. 2972-2980.
|
[4]
|
W. M. Stadler, T. Kuzel, M. Dumas and N. J. Vogelzang, “Multicenter Phase II Trial of Interleukin-2, InterferonAlpha, and 13-Cis-Retinoic Acid in Patients with Metastatic Renal-Cell Carcinoma,” Journal of Clinical Oncology, Vol. 16, No. 5, 1998, pp. 1820-1825.
|
[5]
|
R. I. Fisher, S. A. Rosenberg and G. Fyfe, “Long-Term Survival Update for High-Dose Recombinant Interleukin-2 in Patients with Renal Cell Carcinoma,” The Cancer Journal From Scientific American, Vol. 6, Suppl. 1, 2000, pp. S55-S57.
|
[6]
|
D. F. McDermott, M. M. Regan, J. I. Clark, L. E. Flaherty, G. R. Weiss, T. F. Logan, et al., “Randomized Phase III Trial of High-Dose Interleukin-2 versus Subcutaneous Interleukin-2 and Interferon in Patients with Metastatic Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 23, No. 1, 2005, pp. 133-141.
http://dx.doi.org/10.1200/JCO.2005.03.206
|
[7]
|
S. Negrier, B. Escudier, C. Lasset, J. Y. Douillard, J. Savary, C. Chevreau, et al., “Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma,” The New England Journal of Medicine, Vol. 338, No. 18, 1998, pp. 1272-1278. http://dx.doi.org/10.1056/NEJM199804303381805
|
[8]
|
J. C. Yang, R. M. Sherry, S. M. Steinberg, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, et al., “Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients with Metastatic Renal Cancer,” Journal of Clinical Oncology, Vol. 21, No. 16, 2003, pp. 3127-3132.
http://dx.doi.org/10.1200/JCO.2003.02.122
|
[9]
|
F. Sellner, N. Tykalsky, M. de Santis, J. Pont and M. Klimpfinger “Solitary and Multiple Isolated Metastases of Clear Cell Renal Carcinoma to the Pancreas: An Indication for Pancreatic Surgery,” Annals of Surgical Oncology, Vol. 13, No. 1, 2006, pp. 75-85.
http://dx.doi.org/10.1245/ASO. 2006.03.064
|
[10]
|
O. Strobel, T. Hackert, W. Hartwig, F. Bergmann, U. Hinz, M. N. Wente, et al., “Survival Data Justifies Resection for Pancreatic Metastases,” Annals of Surgical Oncology, Vol. 16, No. 12, 2009, pp. 3340-3349.
http://dx.doi.org/10.1245/s10434-009-0682-3
|
[11]
|
A. D. Sweeney, M. F. Wu, S. G. Hilsenbeck, F. C. Brunicardi, W. E. Fisher, “Value of Pancreatic Resection for Cancer Metastatic to the Pancreas,” Journal of Surgical Research, Vol. 156, No. 2, 2009, pp. 189-198.
http://dx.doi.org/10.1016/j.jss.2009.01.017
|
[12]
|
P. J. Tanis, N. A. van der Gaag, O. R. Busch, T. M. van Gulik and D. J. Gouma, “Systematic Review of Pancreatic Surgery for Metastatic Renal Cell Carcinoma,” British Journal of Surgery, Vol. 96, No. 6, 2009, pp. 579-592.
http://dx.doi.org/10.1002/bjs.6606
|
[13]
|
R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, et al., “Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma,” The New England Journal of Medicine, Vol. 356, No. 2, 2007, pp. 115-124. http://dx.doi.org/10.1056/NEJMoa065044
|
[14]
|
R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, S. Oudard, et al., “Overall Survival and Updated Results for Sunitinib Compared with Interferon Alfa in Patients with Metastatic Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 27, No. 22, 2009, pp. 3584-3590.
http://dx.doi.org/10.1200/JCO.2008.20.1293
|
[15]
|
C. N. Sternberg, I. D. Davis, J. Mardiak, C. Szczylik, E. Lee, J. Wagstaff, et al., “Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial,” Journal of Clinical Oncology, Vol. 28, No. 6, 2010, pp. 1061-1068.
http://dx.doi.org/10.1200/JCO.2009.23.9764
|
[16]
|
A. Ceschia, “2012 ESMO Congress,” The Lancet Oncology, Vol. 13, No. 11, 2012, p. 1081.
|
[17]
|
B. Escudier and V. Kataja, “Renal Cell Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up,” Annals of Oncology, Vol. 21, Suppl. 5, 2010, pp. v137-v139.
http://dx.doi.org/10.1093/annonc/mdq206
|
[18]
|
National Institute for Health and Clinical Excellence, “Sunitinib for the First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma (TA169),” National Institute for Health and Clinical Excellence, London, 2009.
|
[19]
|
J. P. Faure, J. J. Tuech, J. P. Richer, P. Pessaux, J. P. Arnaud and M. Carretier “Pancreatic Metastasis of Renal Cell Carcinoma: Presentation, Treatment and Survival,” Journal of Urology, Vol. 165, No. 1, 2001, pp. 20-22.
http://dx.doi.org/10.1097/00005392-200101000-00005
|
[20]
|
M. E. Gore, C. Szczylik, C. Porta, S. Bracarda, G. A. Bjarnason, S. Oudard, et al., “Safety and Efficacy of Sunitinib for Metastatic Renal-Cell Carcinoma: An Expanded-Access Trial,” The Lancet Oncology, Vol. 10, No. 8, 2009, pp. 757-763.
http://dx.doi.org/10.1016/S1470-2045(09)70162-7
|
[21]
|
D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Global Cancer Statistics, 2002,” CA: A Cancer Journal for Clinicians, Vol. 55, No. 2, 2005, pp. 74-108.
http://dx.doi.org/10.3322/canjclin.55.2.74
|
[22]
|
R. J. Motzer, N. H. Bander and D. M. Nanus, “Renal-Cell Carcinoma,” The New England Journal of Medicine, Vol. 335, No. 12, 1996, pp. 865-875.
http://dx.doi.org/10.1056/NEJM199609193351207
|
[23]
|
A. Antonelli, A. Cozzoli, D. Zani, T. Zanotelli, M. Nicolai, S. C. Cunico, et al., “The Follow-Up Management of Non-Metastatic Renal Cell Carcinoma: Definition of a Surveillance Protocol,” BJU International, Vol. 99, No. 2, 2007, pp. 296-300.
http://dx.doi.org/10.1111/j.1464-410X. 2006.06616.x
|
[24]
|
C. F. Roland and J. A. van Heerden, “Nonpancreatic Primary Tumors with Metastasis to the Pancreas,” Surgery Gynecology & Obstetrics, Vol. 168, No. 4, 1989, pp. 345-347.
|
[25]
|
K. Z’graggen, C. C. Fernandez-del, D. W. Rattner, H. Sigala and A. L. Warshaw, “Metastases to the Pancreas and Their Surgical Extirpation,” Archives of Surgery, Vol. 133, No. 4, 1998, pp. 413-417.
http://dx.doi.org/10.1001/archsurg.133.4.413
|
[26]
|
A. Kassabian, J. Stein, N. Jabbour, K. Parsa, D. Skinner, D. Parekh, et al. “Renal Cell Carcinoma Metastatic to the Pancreas: A Single-Institution Series and Review of the Literature,” Urology, Vol. 56, No. 2, 2000, pp. 211-215.
http://dx.doi.org/10.1016/S0090-4295(00)00639-7
|
[27]
|
E. G. Robbins, D. Franceschi and J. S. Barkin, “Solitary Metastatic Tumors to the Pancreas: A Case Report and Review of the Literature,” The American Journal of Gastroenterology, Vol. 91, No. 11, 1996, pp. 2414-2417.
|
[28]
|
L. E. Harrison, N. Merchant, A. M. Cohen and M. F. Brennan, “Pancreaticoduodenectomy for Nonperiampullary Primary Tumors,” The American Journal of Surgery, Vol. 174, No. 4, 1997, pp. 393-395.
http://dx.doi.org/10.1016/S0002-9610(97)00121-9
|
[29]
|
R. Kanzaki, M. Higashiyama, A. Fujiwara, T. Tokunaga, J. Maeda, J. Okami, et al., “Long-Term Results of Surgical Resection for Pulmonary Metastasis from Renal Cell Carcinoma: A 25-Year Single-Institution Experience,” European Journal Cardio-Thoracic Surgery, Vol. 39, No. 2, 2011, pp. 167-172.
http://dx.doi.org/10.1016/j.ejcts.2010.05.021
|
[30]
|
M. D. Staehler, J. Kruse, N. Haseke, T. Stadler, A. Roosen, A. Karl, et al., “Liver Resection for Metastatic Disease Prolongs Survival in Renal Cell Carcinoma: 12-Year Results from a Retrospective Comparative Analysis,” World Journal of Urology, Vol. 28, No. 4, 2010, pp. 543-547. http://dx.doi.org/10.1007/s00345-010-0560-4
|
[31]
|
R. Ballarin, M. Spaggiari, N. Cautero, N. de Ruvo, R. Montalti, C. Longo, et al., “Pancreatic Metastases from Renal Cell Carcinoma: The State of the Art,” World Journal of Gastroenterology, Vol. 17, No. 43, 2011, pp. 4747-4756. http://dx.doi.org/10.3748/wjg.v17.i43.4747
|
[32]
|
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, et al., “Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma,” The New England Journal of Medicine, 2007, Vol. 356, No. 22, pp. 2271-2281. http://dx.doi.org/10.1056/NEJMoa066838
|
[33]
|
M.E. Gore and J.M. Larkin, “Challenges and Opportunities for Converting Renal Cell Carcinoma into a Chronic Disease with Targeted Therapies,” Br J Cancer, Vol. 104, No. 3, 2011, pp. 399-406.
http://dx.doi.org/10.1038/sj.bjc.6606084
|
[34]
|
B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, M. Staehler, et al., “Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial,” Journal of Clinical Oncology, Vol. 27, No. 20, 2009, pp. 3312-3318.
http://dx.doi.org/10.1200/JCO.2008.19.5511
|